450 related articles for article (PubMed ID: 20229175)
1. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
[TBL] [Abstract][Full Text] [Related]
3. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract][Full Text] [Related]
4. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
8. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
Bertucci F; Finetti P; Viens P; Birnbaum D
Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
[TBL] [Abstract][Full Text] [Related]
9. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
11. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
12. Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.
Liu F; Li Y; Ren M; Zhang X; Guo X; Lang R; Gu F; Fu L
Breast Cancer Res Treat; 2012 Sep; 135(2):459-67. PubMed ID: 22842982
[TBL] [Abstract][Full Text] [Related]
13. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
14. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Witzel I; Loibl S; von Minckwitz G; Mundhenke C; Huober J; Hanusch C; Henschen S; Hauschild M; Lantzsch T; Tesch H; Latos K; Just M; Hilfrich J; Barinoff J; Eulenburg CZ; Roller M; Untch M; Müller V
Breast Cancer Res Treat; 2010 Sep; 123(2):437-45. PubMed ID: 20623180
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
16. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
Breast Cancer Res Treat; 2010 Jan; 119(2):315-23. PubMed ID: 19247830
[TBL] [Abstract][Full Text] [Related]
17. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.
Frati A; Chereau E; Coutant C; Bezu C; Antoine M; Chopier J; Daraï E; Uzan S; Gligorov J; Rouzier R
Breast Cancer Res Treat; 2012 Apr; 132(2):601-7. PubMed ID: 22160638
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]